Rampal on Developments Shaping the Myelofibrosis Treatment Landscape

Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses the evolution of the treatment landscape for patients with myelofibrosis, and notes what he is excited to see more of in the future.

According to Rampal, some of the most practice changing data in the myeloproliferative neoplasm space has led to the FDA approvals of JAK inhibitors. In addition to the JAK inhibitor ruxolitinib (Jakafi), the FDA also has approved fedratinib (Inrebic), and most recently pacritinib (Vonjo), for the treatment of patients with myelofibrosis and severe thrombocytopenia.

In addition to these approvals, a number of trials are ongoing and working to develop new agents that have the potential to completely change the way patients with myelofibrosis are treated. Rampal expects these data to be read out within the next few years.

Transcription:

0:10 | It has changed remarkably, and is changing more now, in the last couple of years, than it has in the last 10 years. In the span of the last few years, we've had fedratinib approved, and pacritinib approved, so that has been a dramatic change.

0:30 | Right now, there are a number of agents that are in phase 3 trials, which you know, all earlier phases of study have looked really good. Those agents, if they are successful in their phase 3 trials, are going to completely change the landscape of how we treat this disease. I think that change will come within the next 2 to 3 years.

0:51 | The number of new drugs that are entering trials and new ideas that are entering into trials is amazing. This is just an exciting time in this field. We've got to see what the data shows us and if any of these things do pan out, but I think that in the next 2-3 years we could see a completely different paradigm and how we choose to treat these patients.